• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Large owner Longitude Capital Partners V, Llc converted options into 3,578,873 shares and bought $18,275,000 worth of shares (1,075,000 units at $17.00) (SEC Form 4)

    2/5/26 7:03:36 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MANE alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Longitude Capital Partners V, LLC

    (Last) (First) (Middle)
    2740 SAND HILL ROAD, SECOND FLOOR

    (Street)
    MENLO PARK CA 94025

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Veradermics, Inc [ MANE ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    02/05/2026
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 02/05/2026 C(1) 1,236,631 A (1) 1,236,631 I See Footnote(2)
    Common Stock 02/05/2026 C(3) 1,171,121 A (3) 2,407,752 I See Footnote(2)
    Common Stock 02/05/2026 C(3) 1,171,121 A (3) 1,171,121 I See Footnote(4)
    Common Stock 02/05/2026 P 192,647 A $17 2,600,399 I See Footnote(2)
    Common Stock 02/05/2026 P 882,353 A $17 2,053,474 I See Footnote(4)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Series B Convertible Preferred Stock (1) 02/05/2026 C 1,236,631 (1) (1) Common Stock 1,236,631 (1) 0 I See Footnote(2)
    Series C Convertible Preferred Stock (3) 02/05/2026 C 1,171,121 (3) (3) Common Stock 1,171,121 (3) 0 I See Footnote(2)
    Series C Convertible Preferred Stock (3) 02/05/2026 C 1,171,121 (3) (3) Common Stock 1,171,121 (3) 0 I See Footnote(4)
    1. Name and Address of Reporting Person*
    Longitude Capital Partners V, LLC

    (Last) (First) (Middle)
    2740 SAND HILL ROAD, SECOND FLOOR

    (Street)
    MENLO PARK CA 94025

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Longitude 103.8 East Partners, LLC

    (Last) (First) (Middle)
    C/O LONGITUDE CAPITAL
    2740 SAND HILL ROAD, SECOND FLOOR

    (Street)
    MENLO PARK CA 94025

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Longitude 103.8 East, L.P.

    (Last) (First) (Middle)
    C/O LONGITUDE CAPITAL
    2740 SAND HILL ROAD, SECOND FLOOR

    (Street)
    MENLO PARK CA 94025

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Longitude Venture Partners V, L.P.

    (Last) (First) (Middle)
    C/O LONGITUDE CAPITAL
    2740 SAND HILL ROAD, SECOND FLOOR

    (Street)
    MENLO PARK CA 94025

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.
    2. These shares are held by Longitude Venture Partners V, L.P. ("LVPV"). Longitude Capital Partners V, LLC ("LCPV"), is the general partner of LVPV and may be deemed to have voting, investment and dispositive power with respect to these shares. Juliet Tammenoms Bakker and Patrick Enright, a member of the board of directors of the Issuer, are the managing members of LCPV, and may each be deemed to share voting, investment and dispositive power with respect to these shares. Each of LCPV, Ms. Tammenoms Bakker and Patrick Enright disclaims beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.
    3. On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.
    4. These shares are held by Longitude 103.8 East, L.P. ("L103"). Longitude 103.8 East Partners, LLC ("L103P") is the general partner of L103 and may be deemed to have voting, investment and dispositive power with respect to these shares. Juliet Tammenoms Bakker and Patrick Enright, a member of the board of directors of the Issuer, are the managing members of L103P, and may each be deemed to share voting, investment and dispositive power with respect to these shares. Each of L103P, Ms. Tammenoms Bakker and Patrick Enright disclaims beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.
    Remarks:
    /s/ Cristiana Oliveira 02/05/2026
    /s/ Cristiana Oliveira 02/05/2026
    /s/ Cristiana Oliveira 02/05/2026
    /s/ Cristiana Oliveira 02/05/2026
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MANE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MANE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MANE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Suvretta Capital Management, Llc bought $10,542,478 worth of shares (282,674 units at $37.30) (SEC Form 4)

    4 - Veradermics, Inc (0001827635) (Issuer)

    2/9/26 6:28:51 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Coric Vlad converted options into 638,262 shares and bought $1,999,982 worth of shares (117,646 units at $17.00), increasing direct ownership by 913% to 129,939 units (SEC Form 4)

    4 - Veradermics, Inc (0001827635) (Issuer)

    2/5/26 7:04:25 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Childs John W converted options into 1,907,889 shares and bought $4,999,989 worth of shares (294,117 units at $17.00) (SEC Form 4)

    4 - Veradermics, Inc (0001827635) (Issuer)

    2/5/26 7:04:00 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MANE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell

    NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Feb. 12, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Ashley Mastronardi delivers the pre-market update on February 12th Markets are higher after mixed reactions to yesterday's hotter than expected Jobs Report as the Bureau of Labor Statistics reported that the U.S. economy added 130,000 jobs.Forgent Power Solutions (NYSE:FPS) is celebrating its early February IPO this morning with shares having jumped 22% since trading

    2/12/26 8:55:00 AM ET
    $FPS
    $ICE
    $MANE
    Industrial Machinery/Components
    Energy
    Investment Bankers/Brokers/Service
    Finance

    Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss

    This marks the completion of enrollment of all male Phase 3 studies of VDPHL01 in pattern hair loss, with approximately 1,000 male patients enrolled across studies Topline data from initial '302' trial anticipated in the first half of 2026; '304' confirmatory study topline data anticipated in the second half of 2026 VDPHL01, if approved, has the potential to be the first and only non-hormonal oral FDA approved treatment for men and women with pattern hair loss, a condition affecting an estimated 50 million men and 30 million women in the United States Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing

    2/9/26 7:30:00 AM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veradermics Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering

    Veradermics, Incorporated ("Veradermics"), (NYSE:MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced the closing of its previously announced upsized initial public offering of 17,339,294 shares of its common stock at an initial public offering price of $17.00 per share, including 2,261,647 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares. The gross proceeds from the offering were approximately $294.8 million, before deducting underwriting discount and commissions and estimated offering expenses. All o

    2/5/26 4:05:00 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MANE
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Veradermics Incorporated

    SCHEDULE 13G - Veradermics, Inc (0001827635) (Subject)

    2/12/26 4:54:55 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13D filed by Veradermics Incorporated

    SCHEDULE 13D - Veradermics, Inc (0001827635) (Subject)

    2/11/26 5:22:51 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Veradermics Incorporated

    S-8 - Veradermics, Inc (0001827635) (Filer)

    2/5/26 5:05:11 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MANE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Suvretta Capital Management, Llc bought $10,542,478 worth of shares (282,674 units at $37.30) (SEC Form 4)

    4 - Veradermics, Inc (0001827635) (Issuer)

    2/9/26 6:28:51 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Suvretta Capital Management, Llc claimed ownership of 3,886,317 shares (SEC Form 3)

    3 - Veradermics, Inc (0001827635) (Issuer)

    2/9/26 6:13:03 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Pance Katarina

    4 - Veradermics, Inc (0001827635) (Issuer)

    2/5/26 7:12:52 PM ET
    $MANE
    Biotechnology: Pharmaceutical Preparations
    Health Care